Hytrin 1mg tablets

Land: Bretland

Tungumál: enska

Heimild: MHRA (Medicines & Healthcare Products Regulatory Agency)

Virkt innihaldsefni:

Terazosin hydrochloride

Fáanlegur frá:

Advanz Pharma

ATC númer:

G04CA03

INN (Alþjóðlegt nafn):

Terazosin hydrochloride

Skammtar:

1mg

Lyfjaform:

Oral tablet

Stjórnsýsluleið:

Oral

Tegund:

No Controlled Drug Status

Gerð lyfseðils:

Invalid to prescribe in NHS primary care

Vörulýsing:

BNF:

Upplýsingar fylgiseðill

READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR
YOU.
•
Please keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or
pharmacist.
•
This medicine has been prescribed for you ONLY. Do not pass
it on to others. It may harm them, even if their symptoms are
the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist.
This includes any possible side effects not listed in this leaflet.
See section 4.
WHAT IS IN THIS LEAFLET:
1. What Hytrin Tablets are and what they are used for
2. What you need to know before you take Hytrin
Tablets
3. How to use Hytrin Tablets
4. Possible Side Effects
5. How to Store Hytrin Tablets
6. Contents of the pack and other information
1. WHAT HYTRIN TABLETS ARE AND WHAT THEY ARE
USED FOR
The name of your medicine is Hytrin 1 mg, 2 mg, 5 mg, or 10mg
Tablets (called Hytrin Tablets in this leaflet). Hytrin Tablets
contains the active ingredient terazosin. Terazosin belongs to a
group of medicines called alpha-blockers. Hytrin Tablets are used
in adults to treat high blood pressure. Hytrin Tablets are also
used in adults for the treatment of a condition called benign
prostatic hyperplasia (BPH) which affects the prostate and is
common in older men. This condition stops the flow of urine from
the bladder and can lead to symptoms such as a weak or
interrupted urine flow, a need to pass water more frequently
and/or a sudden need to pass water. Hytrin Tablets can relax the
muscle of the prostate gland and bladder exit to help relieve
these symptoms.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE HYTRIN
TABLETS
DO NOT TAKE HYTRIN TABLETS IF YOU:
•
are allergic to terazosin, or any of the following drugs:
alfuzosin, indoramin, prazosin, tamsulosin, doxazosin, or to
any of the other ingredients contained in this medicine listed
in section 6 (allergic reactions include mild symptoms such as
itching and/or rash. More severe symptoms include swelling
of the fa

Vara einkenni

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Hytrin 1 mg Tablets
Terazosin 1 mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 1 mg of terazosin as monohydrochloride dihydrate.
Excipients with known effect:
Lactose
(128.56 mg)
For a full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
White, round, flat bevelled tablets embossed with logo and triangular
facets on
one face and plain on the other.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Orally administered Hytrin is indicated in adults for the treatment of
mild to
moderate hypertension. It may be used in combination with thiazide
diuretics
and/or other antihypertensive drugs or as sole therapy where other
agents are
inappropriate or ineffective. The hypotensive effect is most
pronounced on the
diastolic pressure. Although the exact mechanism of the hypotensive
action of
terazosin is not established, the relaxation of peripheral blood
vessels appears
to be produced mainly by competitive antagonism of post-synaptic
alpha-1-
adrenoceptors. Hytrin usually produces an initial gradual decrease in
blood
pressure followed by a sustained antihypertensive action.
Orally administered Hytrin is also indicated in adults as a therapy
for the
symptomatic treatment
of urinary
obstruction
caused by
benign prostatic
hyperplasia (BPH). Terazosin is a selective post synaptic
alpha-1-adrenoceptor
blocker. Antagonism of alpha-1-receptors on prostatic and urethral
smooth
muscle has been shown to improve urinary tract flow and relieve the
urinary
obstruction caused by BPH.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
HYPERTENSION.
_Adults _
Initial dose
1mg before bedtime is the starting dose for all patients and should
not be
exceeded. Compliance with this initial dosage recommendation should be
strictly
observed
to
minimise
potential
for
acute
first-dose
hypotensive
episodes.
Subsequent doses
The single daily dosage may be increased by approximately doubling the
dosage at weekly intervals to achieve the desired b